The 5 NeuroTech Companies That Could Be the Next Billion-Dollar Bet
Brain-computer interfaces are leaving the lab — and these five companies are the ones investors, doctors, and early adopters should be watching right now.
There’s a strange thing happening in neurotech. The money is serious now. Not “hopeful seed round” serious — more like “Bezos, Gates, and OpenAI writing nine-figure checks” serious. According to the BCI Intel 2026 Annual Industry Report, more than $1.6 billion has been raised across the brain-computer interface space in 2025–2026 year-to-date. That number would have been laughable five years ago. Today, it barely raises an eyebrow.
But here’s what matters more than the headline figures: the clinical results are starting to hold up. Patients are playing chess with their thoughts. Paralyzed individuals are browsing the web using only their minds. A closed-loop brain device is stopping seizures before patients even feel them coming. This is no longer the sci-fi section of a bookstore — it’s a regulated, FDA-scrutinized, peer-reviewed reality that’s moving faster than most people realize.
If you’re a neurotech early adopter, the question isn’t whether this space produces a billion-dollar company. It’s which one crosses that line next — and whether you’re paying attention before it happens. As we covered in our piece on why neurotech is approaching a tipping point, the signals are stacking up. What follows is a look at the five companies where that stack is tallest.
Synchron: the “no open-brain surgery” pitch is actually working 🧠
If you had to design a BCI company that could navigate hospital procurement, nervous surgeons, and skittish regulators all at once, you’d probably invent something close to Synchron. Based in Brooklyn, New York, Synchron has built the Stentrode — an endovascular brain-computer interface that reaches the brain through the blood vessels rather than through a craniotomy. Threading it in via the jugular vein, the way you’d place a cardiac stent, the Stentrode sits inside a blood vessel near the motor cortex and listens.
That single design choice — no open-brain surgery — gives Synchron a compelling pitch to clinicians who would never refer a patient for a more invasive procedure. The company completed its U.S. feasibility trial and is now preparing for a full pivotal study targeting FDA Pre-Market Approval, with enrollment expected across four or more sites in 2026. Ten patients have been implanted to date across the U.S. and Australia.
The investor roster tells you something. Synchron’s $200 million Series D in November 2025, led by Double Point Ventures, brought total funding to $345 million — and the company described its valuation as “nearly $1 billion.” That round included Bezos Expeditions, Gates Frontier, Khosla Ventures, and ARCH Venture Partners. When you have Bill Gates and Jeff Bezos backing the same startup, it’s a reasonable signal that the technology has passed some serious due diligence filters.
What separates Synchron from the crowded field of implantable BCI aspirants:
A Stentrode platform already integrated with Apple’s BCI human interface device protocol, enabling thought-controlled iPad experiences in clinical demonstrations
Active partnership with NVIDIA Holoscan for real-time neural signal processing
The unveiling of Chiral, described as the world’s first Cognitive AI Brain Foundation Model, announced in March 2025
A regulatory path that’s genuinely differentiated — the low-invasiveness of the procedure reduces the barrier for a pivotal trial
The honest complication is signal quality. Threading an electrode through a blood vessel and parking it near the brain captures fewer neurons than going directly in. Synchron’s bet is that the access advantage outweighs the resolution trade-off — especially as AI signal decoding improves. So far, the clinical data suggests that bet is reasonable.
Precision Neuroscience: surface-level thinking, literally 💡
Precision Neuroscience occupies an interesting middle ground. Founded by Benjamin Rapoport, a co-founder of Neuralink who left to pursue a less invasive approach, the company’s Layer 7 Cortical Interface is an ultra-thin, flexible micro-electrode film that lays on the surface of the brain rather than penetrating it. Think of it as a contact lens for your cortex — 1,024 channels of neural recording, inserted through a small skull opening the size of a dime.
The company cleared a significant regulatory hurdle with its FDA 510(k) clearance for temporary implantation up to 30 days — a credential that allowed it to begin first-in-human implants in 2024 during routine neurosurgery. That’s strategically smart: by piggybacking on existing brain surgeries (epilepsy mapping, tumor resection), Precision is collecting real human neural data without needing to run standalone clinical trials for every implant. They’re playing the long game beautifully.
Here’s why the architecture matters for investors and technologists:
Surface placement means no tissue damage from needle penetration — relevant for regulatory timelines and physician acceptance
The film’s flexibility lets it conform to the brain’s surface, maintaining signal quality over time without rigid electrode drift
The surgical simplicity of a 510(k)-cleared temporary implant creates a commercial wedge before the chronic wireless version is approved
Precision is reportedly in the IPO conversation, alongside Synchron and Neuralink, per financial reporting from MarketWise
The road ahead is still long. Precision’s chronic wireless implant — the version that would actually live in a patient full-time — is still in development, with a first-in-human chronic test expected in 2026. That’s the version that would generate real medical device revenue at scale. Getting from temporary surgical tool to permanent neural interface is not a trivial regulatory step. But the team’s pedigree is hard to dismiss, and the Layer 7 approach may prove uniquely attractive to hospitals that already perform thousands of brain surgeries per year. 🔬
The question that keeps me interested: if your cortical interface doesn’t poke holes in brain tissue, what does long-term data show about signal stability? The answer to that question — expected over the next 18 months — may define Precision Neuroscience’s trajectory more than any funding round.
Paradromics: thinking bigger when bigger is actually necessary ⚡
Most BCI companies talk about channel counts the way car ads talk about horsepower: enthusiastically, and occasionally with more emphasis than the real-world utility justifies. Paradromics is the exception. The Austin-based company is developing the Connexus platform — a cortical implant targeting 65,000 simultaneous neural channels with a bidirectional data streaming architecture that separates it from every rival in the space.
To understand why that number matters: Neuralink’s N1 chip records from around 3,072 electrodes. A high channel count means higher resolution brain mapping, richer signal decoding, and more complex applications — from high-fidelity speech restoration to eventually reading fine motor commands for robotic limb control. The jump from 3,000 channels to 65,000 isn’t incremental. It’s a different class of ambition.
Paradromics took a real milestone in June 2025, completing its first-in-human recording during epilepsy surgery — demonstrating safe implantation, data capture, and removal in under twenty minutes. The company holds $127 million in total funding, plus approximately $18 million in NIH and DARPA grants — the kind of non-dilutive federal backing that says something about the seriousness of the technology.
A few distinguishing details worth knowing:
The NEOM Investment Fund participated in Paradromics’ Series B in February 2025 — a signal that Middle Eastern sovereign capital is taking BCI infrastructure seriously
The Connect-One system, Paradromics’ first chronic speech restoration implant, is on the 2026 milestone roadmap
The company’s architecture uses separate cranial and chest components, reducing heat and size constraints in the implanted brain portion
Paradromics has received FDA Breakthrough Device designation, which shortens regulatory review timelines meaningfully
The real risk here is execution pace. The gap between a first-in-human recording and a commercially deployable chronic implant is measured in years and clinical trial patients. Paradromics is early — earlier than Synchron, probably earlier than Precision — but the ceiling is arguably higher if the high-bandwidth thesis holds. If you believe that the most valuable BCI applications will require richly detailed neural data rather than coarse-grained signals, Paradromics is building the pipes to carry it.
Merge Labs: when Sam Altman bets on your brain 🚀
The strangest story in neurotech right now — and the one with the most complicated optics — is Merge Labs. The company emerged from stealth in January 2026 having raised $252 million from a funding round led by OpenAI, at an $850 million valuation. It was co-founded by Sam Altman, who also happens to be the CEO of OpenAI, the company that wrote the check. As the Financial Times and others noted, that circular structure raised some eyebrows. And fairly so.
But stripped of the governance drama, what Merge Labs is actually building is interesting. The company is pursuing non-invasive, ultrasound-based brain-computer interfaces — using focused ultrasound to read and potentially write neural activity through the skull, without any implant whatsoever. The scientific foundation overlaps with Forest Neurotech, another ultrasound BCI effort backed by Eric Schmidt. Caltech neuroscientist Mikhail Shapiro, who has published extensively on ultrasound neuromodulation, is part of the founding leadership.
Why is this approach worth attention?
No surgery means a path to consumer applications that invasive BCIs simply can’t reach — at least not for decades
Focused ultrasound has spatial resolution far superior to EEG, potentially approaching MRI-like localization without the machine the size of a small car
The combination of Altman’s network and OpenAI’s involvement all but guarantees that AI-driven neural decoding will be a core capability from the start
With an $850 million valuation pre-revenue, Merge Labs’ eventual IPO (whenever it comes) will move every public name in the BCI supply chain
The honest caveat: Merge Labs has no public clinical results yet. Zero. The 2026 roadmap includes “first technical demonstrations” of the platform — which is another way of saying they’re still in the proof-of-concept phase. Altman’s involvement guarantees attention, but it doesn’t guarantee the physics cooperates. Focused ultrasound for BCI is real science with real promise, but it’s less mature than the implantable approaches. Anyone calling this a sure thing is speculating, not analyzing.
That said, if the non-invasive route cracks even 20% of the signal quality that Synchron achieves endovascularly, the addressable market expands by orders of magnitude. That’s the asymmetric bet. What do you think — does a no-surgery BCI actually change mass adoption, or is the clinical population already large enough to build a big company without consumer applications?
NeuroPace: the quiet company that quietly started making money 📈
NeuroPace doesn’t show up in most “hot neurotech startups” articles, partly because it’s been around since 1997 and partly because it’s already public — listed on NASDAQ under the ticker NPCE. But that’s exactly why it belongs on this list. While everyone else is burning venture capital on feasibility studies, NeuroPace posted its first-ever positive adjusted EBITDA quarter in late 2025. That’s not a press release milestone. That’s a company proving that a brain device can actually sustain a business.
The product is the RNS (Responsive Neurostimulation) System — and if you haven’t heard of it, you’re about to understand why it’s remarkable. The RNS is a closed-loop brain device: it doesn’t just deliver electrical stimulation, it listens first. A small unit sits in the skull, monitoring brainwaves around the clock, learning the specific electrical signatures that precede a seizure. When it detects that pattern, it fires a micro-pulse to interrupt the cascade — usually before the patient experiences any symptoms at all. It’s the world’s first brain device that predicts and preempts, rather than responding after the fact.
What NeuroPace is doing in 2026 that makes it a watch-list name:
The “Nautilus” project — a next-generation RNS with a smaller form factor designed to make the cranial surgery less invasive, targeting earlier intervention in the treatment timeline
The adolescent mental health expansion is an adjacent path: in November 2025, the FDA cleared BrainsWay’s Deep TMS for severe depression in adolescents, validating the regulatory appetite for non-pharmacological neuro interventions. NeuroPace, with its closed-loop expertise, is well-positioned for adjacent indications
A profitability inflection that changes the risk profile completely — this isn’t a company racing to prove viability; it’s a company proving durability
Existing CPT codes and insurance reimbursement that eliminate one of the hardest commercial problems in medtech
The category NeuroPace occupies — call it “brain pacemakers” — is already the most mature, revenue-stable corner of neurotech. Insurance pays for it. Doctors know how to implant it. The patient population is real and large: roughly 1 in 100 people have epilepsy, and about a third of those don’t respond to medication. That’s millions of potential patients globally, with a device that’s already approved and reimbursed.
I find NeuroPace the most underrated name in this space precisely because it lacks the Musk glow or the Altman mystique. Its story is slower, quieter, and much more likely to compound. The “Nautilus” form factor, if it ships on schedule in 2026 or 2027, could meaningfully expand the implanting physician pool. And for a company that just crossed into profitability, that’s not a moonshot — it’s a roadmap. 🧬
The through-line: what to actually watch for
Every article about “companies to watch” owes you a framework for how to watch them. So here’s mine, borrowed from what I think the data actually supports in 2026.
The BCI market is splitting into two distinct tracks. The first is the clinical restoration track — paralysis, ALS, epilepsy, vision loss. Revenue comes from hospitals, reimbursed by insurance, priced at $50,000–$200,000 per implant. Synchron, Precision Neuroscience, Paradromics, and NeuroPace live here. The second track is the consumer enhancement track — productivity, gaming, mental wellness, eventually cognitive augmentation. Merge Labs is angling for this, and so are consumer neurotech device makers in the non-invasive space.
The milestones that will actually move the needle:
Any S-1 filing from Synchron, Precision, or Merge Labs — the first neurotech IPO after Neuralink’s will reprice every name in the sector
Pivotal trial enrollment for Synchron in 2026 — this is the last major clinical hurdle before a PMA application
Paradromics’ Connect-One chronic speech implant results — the first high-channel-count chronic data will either validate or deflate the 65,000-channel thesis
NeuroPace’s Nautilus launch — a smaller device means broader physician adoption, which means revenue growth that doesn’t require a category expansion
Any regulatory signal on ultrasound BCI — the FDA hasn’t yet defined a pathway for focused ultrasound neural interfaces, and that ambiguity is Merge Labs’ biggest near-term risk
As we wrote in our analysis of what gives neurotech companies lasting competitive advantages, the moat in this space is built from IP, clinical data, and physician relationships — not from press coverage or famous co-founders. That’s worth remembering before deciding which of these five stories has staying power.
The brain is the final frontier of medicine. It has been for decades. What’s new is that the tools to navigate it are finally keeping pace with the ambition. The question is which companies build those tools well enough to still be standing when the real commercial window opens — and right now, these five are the ones making the strongest case. So: which of these bets would you be willing to place? 👇